Table 2.

Functional outcome at 90 days (mRS90d 0–2 vs. 3–6) and baseline characteristics.

		n	%	mRS 3–6	mRS 0–2	OR (95%-KI)	p-value*	p-value**
Gender	Female	100	43.3	67 (67.0%)	33 (33.0%)	Ref.	0.311
	Male	131	56.7	96 (73.3%)	35 (26.7%)	0.74 (0.42–1.31)
Age	<70	79	34.2	50 (63.3%)	29 (36.7%)	Ref.	0.155
	70–79	84	36.4	60 (71.4%)	24 (28.6%)	0.69 (0.36–1.33)		0.316
	≥80	68	29.4	53 (77.9%)	15 (22.1%)	0.49 (0.23–1.02)		0.071
Symptom onset	Non-witnessed	82	35.5	64 (78.0%)	18 (22.0%)	Ref.	0.071
	Witnessed	149	64.5	99 (66.4%)	50 (33.6%)	1.80 (0.96–3.36)
Diabetes mellitus	No	128	67.7	79 (61.7%)	49 (38.3%)	Ref.	0.001
	Yes	61	32.3	52 (85.2%)	9 (14.8%)	0.28 (0.13–0.62)
Cholesterol	No	130	68.8	94 (72.3%)	36 (27.7%)	Ref.	0.130
	Yes	59	31.2	36 (61.0%)	23 (39.0%)	1.67 (0.87–3.20)
Smoker	No	159	86.4	115 (72.3%)	44 (27.7%)	Ref.	0.020
	Yes	25	13.6	12 (48.0%)	13 (52.0%)	2.83 (1.20–6.69)
Hypertension	No	38	17.4	28 (73.7%)	10 (26.3%)	Ref.	0.844
	Yes	180	82.6	127 (70.6%)	53 (29.4%)	1.17 (0.53–2.58)
Pre-PCASPECT cMRI	≤ 7	24	38.7	18 (75.0%)	6 (25.0%)	Ref.	0.188
	>7	38	61.3	22 (57.9%)	16 (42.1%)	2.18 (0.70–6.79)
Pre-PCASPECT cCT	≤ 7	13	8.4	10 (76.9%)	3 (23.1%)	Ref.	0.760
	>7	142	91.6	101 (71.1%)	41 (28.9%)	1.35 (0.35–5.19)
Admission NIHSS	0–4	27	17.4	7 (25.9%)	20 (74.1%)	Ref.	<0.001	0.067
	5–11	35	22.6	18 (51.4%)	17 (48.6%)	0.33 (0.11–0.98)		<0.001
	12–22	53	34.2	44 (83.0%)	9 (17.0%)	0.07 (0.02–0.22)		<0.001
	23–27	18	11.6	16 (88.9%)	2 (11.1%)	0.04 (0.01–0.24)		<0.001
	≥28	22	14.2	22 (100%)	0 (0%)

^*Global p-value,

^**p-value for each subgroup if exceeding more than two subgruops.